A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naive High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE) EA8212
Objective
Primary Objectives To determine the event free survival (EFS) of BCG-naive high grade non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical BCG vs GEMDOCE.
Secondary Objectives To compare changes in cancer-specific and bladder cancer-specific QOL from baseline to treatment between BCG-naive high grade NMIBC patients receiving BCG and GEMDOCE.
To determine the cystectomy free survival (CFS) of BCG-naive high grade NMIBC patients treated with intravesical BCG vs GEMDOCE.
To determine the progression free survival (PFS) of BCG-naive high grade NMIBC patients treated with intravesical BCG vs GEMDOCE.
To determine the safety and toxicity of BCG-naive high grade NMIBC patients treated with intravesical BCG vs GEMDOCE.
